A
10.09
0.22 (2.23%)
| Penutupan Terdahulu | 9.87 |
| Buka | 9.89 |
| Jumlah Dagangan | 69,290 |
| Purata Dagangan (3B) | 84,730 |
| Modal Pasaran | 62,089,644 |
| Harga / Jualan (P/S) | 32.07 |
| Harga / Buku (P/B) | 0.820 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -6,187.46% |
| EPS Cair (TTM) | -17.47 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -68.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.76% |
| Nisbah Semasa (MRQ) | 7.56 |
| Aliran Tunai Operasi (OCF TTM) | -78.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -44.94 M |
| Pulangan Atas Aset (ROA TTM) | -38.74% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Aligos Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.13 |
|
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.44% |
| % Dimiliki oleh Institusi | 65.63% |
| Julat 52 Minggu | ||
| Median | 50.00 (395.54%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Sep 2025 | 50.00 (395.54%) | Beli | 10.20 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 Nov 2025 | Pengumuman | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10 Nov 2025 | Pengumuman | Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 |
| 06 Nov 2025 | Pengumuman | Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results |
| 04 Nov 2025 | Pengumuman | Aligos Therapeutics to Present at Upcoming Investor Conferences |
| 30 Oct 2025 | Pengumuman | Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 |
| 17 Oct 2025 | Pengumuman | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 16 Oct 2025 | Pengumuman | Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 |
| 14 Oct 2025 | Pengumuman | Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference |
| 07 Oct 2025 | Pengumuman | Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |